Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

To study whether three concentrations of oxygen used during operation Will affect the ability to fight infections undergoing in patients under going surgery for cancer of large intestine – An experimental study

ABSTRACT: Intervention1: Group_0.5: Group_0.5 will receive 50% oxygen during the operation Intervention2: Group_0.8: Group_0.8 will receive 80% oxygen during the operation Control Intervention1: Group_0.3: Group_0.3 will receive 30% oxygen during the operation Primary outcome(s): The primary end point of the study will be effect of different FiO2 on NK cell count (CD56, CD6)Timepoint: Perioperative period Study Design: Randomized, Parallel Group, Multiple Arm Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:On-site computer system Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

DISEASE(S): Malignant Neoplasm Of Colon

PROVIDER: 28260 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Sedation of children prior to the surgery using nebulization of two doses of a same drug called dexmedetomidine to reduce parental separation anxiety.

Project description:Intervention1: Group B - 39 patients, 3 microgram/kg dexmedetomidine mixed in normal saline to make a total volume of 3 ml.: Group B will receive nebulisation with dexmedetomidine at a dose 3mcg/kg diluted with 0.9% normal saline to a total volume of 3 ml with a nebuliser face mask and a continuous flow of 100% oxygen at 6 L/min for 10 min once before induction of anaesthesia in sitting position. Control Intervention1: Group A - 39 patients, 2 microgram/kg of dexmedetomidine mixed in normal saline to a total volume of 3 ml.: Group A will receive nebulisation with dexmedetomidine at a dose 3mcg/kg diluted with 0.9% normal saline to a total volume of 3 ml with a nebuliser face mask and a continuous flow of 100% oxygen at 6 L/min for 10 min once before induction of anaesthesia in sitting position. Primary outcome(s): Parental seperation anxiety score and mask acceptance scoreTimepoint: 30 mins after beginning of nebulisation. Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant Blinded

| 2722103 | ecrin-mdr-crc

Comparison of intubation using instruments as Ambu Auragain,fastrach LMA and Blockbuster LMA.

Project description:Intervention1: Tracheal intubation with supraglottic Airway devices: Comparison of tracheal intubation with Ambu AuraGain,fastrach Laryngeal Mask and Blockbuster Laryngeal Mask Airway. Control Intervention1: Ambu AuraGain: Tracheal intubation with Ambu AuraGain Control Intervention2: Fastrach Laryngeal Mask Airway: Tracheal intubation with Fastrach Laryngeal Mask Airway. Control Intervention3: Blockbuster Laryngeal Mask Airway: Tracheal intubation with Blockbuster Laryngeal Mask Airway. Primary outcome(s): First Attempt success rate of tracheal intubation.Timepoint: During intubation Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Outcome Assessor Blinded

| 2605805 | ecrin-mdr-crc

Effect of a drug (Oral Ivabradine) on BP and Heart Rate during putting endotracheal tube with laryngoscopy.

Project description:Intervention1: Tablet Ivabradine: Oral Ivabradine 5mg was given one hour before surgery Control Intervention1: tablet multivitamin: oral multivitamin(one tablet) one hour before surgery Primary outcome(s): Haemodynamics changesTimepoint: up to 10 min after laryngoscopy and intubation Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2757961 | ecrin-mdr-crc

Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis

Project description:This was a phase II, randomized, placebo-controlled, double-blinded single center study (clinicaltrials.gov: NCT01806662) to investigate safety and efficacy of ustekinumab treatment in moderate-to-severe AD patients. Patients underwent 1:1 randomization using a computer generated subject randomization table by an unblinded pharmacist. to Subjects received subcutaneous ustekinumab or placebo at weeks 0, 4, and 16 with a crossover to the other agent (either ustekinumab or placebo) at weeks 16, 20, and 32 (Figure 1A) to ensure patient retention.

2019-11-20 | GSE140684 | GEO

Does local application of nitrates, during insertion of staplers via anal canal for bowel anastomosis prevent injury to muscles of anal canal ?

Project description:Intervention1: 0.2% Glyceryl Trinitrate: 1mg 0.2% glyceryl trinitrate, which corresponds to 2cm on the standardized measuring scale Control Intervention1: Nil: Nil Primary outcome(s): To compare anal sphincter pressure between intervention and observation groupsTimepoint: 1-3 days preoperative and 14-30 days postoperative Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant and Outcome Assessor Blinded

| 2579582 | ecrin-mdr-crc

A phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

Project description:Intervention1: Masitinib, FOLFIRI: Masitinib will be taken orally, daily at 6mg/kg/day. FOLFIRI will be administered every 2 weeks Control Intervention1: Placebo, FOLFIRI: Placebo will be taken orally, daily. FOLFIRI will be administered every 2 weeks Primary outcome(s): Overall Survival (OS)Timepoint: till death or last follow up Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant and Investigator Blinded

| 2577140 | ecrin-mdr-crc

Use of ultrasound to measure stomach volume in patients who take a carbohydrate drink versus fully fasted patients before surgery.

Project description:Intervention1: Maltdextrin drink (Carboload): The patients randomised in Group C will receive 800 ml Carboload feeding at around 10 PM the night before surgery and further 400 mL Carboload at around 6 AM on the morning of surgery. Control Intervention1: Fasting: The patients in Group F will be fasted overnight and allowed water till 6 hours before surgery. Primary outcome(s): The primary outcome to be measured in the study will be the RGV (in mL) measured with ultrasound.Timepoint: Just before induction of anaesthesia. Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Outcome Assessor Blinded

| 76748 | ecrin-mdr-crc

Comparison between decreasing body temperature and keeping normal temperature before starting heated chemotherapy into abdomen on developing decreased body temperature after heated chemotherapy

Project description:Intervention1: Normothermia Group: Normothermia will be maintained throughout CRS and warming devices will not be stopped before starting HIPEC. Control Intervention1: Passive Hypothermia Before HIPEC: As per our standard anesthesia protocol, warming devices will be stopped 1 hour before the HIPEC phase to maintain temperature between 34.5-35.0 degree C. Primary outcome(s): Proportion of patients who have achieved normal body temperature of at least 35 degree C post HIPECTimepoint: Immediately (0 hour) after shifting the patients to ICU or postanaesthesia care unit. Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:On-site computer system Blinding and masking:Open Label

| 78212 | ecrin-mdr-crc

A clinical trial to study the effects of two drugs, R-TPR-023 and Avastinâ?¢ in patients with Metastatic colorectal cancer

Project description:Intervention1: R-TPR-023: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years. Control Intervention1: Avastinâ?¢: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years Primary outcome(s): Outcome Name: Efficacy will be assessed as Objective Response Rate (Complete Response and Partial Response) by RECIST 1.1 criteria at 25 weeksTimepoint: 25 weeks Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2574628 | ecrin-mdr-crc

Phase III, Multi-centre, Double Blind, Randomized Placebo Controlled Trial of Aspirin for Duke C and High Risk Dukes B Colorectal Cancers

Project description:Intervention1: Aspirin: 200 mg OD for 3 years Control Intervention1: Placebo: 200 mg OD for 3 years Primary outcome(s): 1. Disease free survival for all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer ptient sub groups)Timepoint: 3 years;Disease free survival for colon cancer (high risk Dukes B and Dukes C colon cancer)Timepoint: 3 years Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 2572425 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data